| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Hepatitis A Total Antibody
MessageThis assay tests for both IgG and IgM antibodies to Hepatitis A as an aid to determine the presence of antiboy response to Hep A Vrius in vaccine recipients.
Test Code
HAVT
CPT Codes
86708
Preferred Specimen
1.0 mL Serum or Plasma
Minimum Volume
50 uL
Other Acceptable Specimens
Tiger top (SST)
Gold top (SST)
Red top
Plasma –EDTA (Lavender)
Gold top (SST)
Red top
Plasma –EDTA (Lavender)
Transport Temperature
Refrigerated
Specimen Stability
Room Temperature: N/A
Refrigerated: 7 days at 2-8 deg C
Frozen: 3 months at -20 deg C; Samples may be frozen and thawed up to 5 times.
Timing Considerations: Serum and plasma should be separated from the cells within 2 hours from the time of collection.
Refrigerated: 7 days at 2-8 deg C
Frozen: 3 months at -20 deg C; Samples may be frozen and thawed up to 5 times.
Timing Considerations: Serum and plasma should be separated from the cells within 2 hours from the time of collection.
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Samples not labeled with complete first and last name and date of birth.
Grossly hemolyzed.
Grossly hemolyzed.
Methodology
Electrochemiluminescence immunoassay
Setup Schedule
Sun - Sat
Report Available
Same day
Reference Range
Non-reactive
Clinical Significance
For the detection of total antibodies (IgM and IgG) to hepatitis A virus in human serum and plasma. The assay is intended for use as an aid in the laboratory diagnosis of past or acute/recent hepatitis A infection. Assay results, in conjunction with other laboratory results and clinical information, may be used to provide presumptive evidence of infection with hepatitis A virus in persons with signs or symptoms of hepatitis and in persons at risk for hepatitis A infection, or used as an aid to determine the presence of antibody response to HAV in vaccine recipients.
The hepatitis A virus is an RNA-containing virus that lacks an envelope. It belongs to the family of picornaviruses. To date, just one human serotype and 7 genotypes have been described. The viral capsid consists of 3 proteins (VP1-VP3) that form an immunodominant structure on the surface of the viral particle that is highly conserved between all genotypes. After vaccination or natural infection, the immune response is directed against this structure.
Hepatitis A is the most common form of acute viral hepatitis. It is transmitted by the fecal-oral route. The disease has not been known to take a chronic course, nor does the virus persist in the organism. The hepatitis A virus is one of the most common causes (10-20 %) of a fulminating course of viral hepatitis.
Total anti-HAV is positive at the onset of a hepatitis A infection (IgM). After natural infection, anti-HAV IgG antibodies can usually be detected lifelong and provide protection against the disease if the organism is reinfected. Vaccines against hepatitis A and combined vaccines against hepatitis A and B are available today. Upon vaccination against hepatitis A, anti-HAV IgG antibodies can be detected after 2 weeks. In the case of complete immunization, protection usually lasts for years. There is no limit value to define immune protection but anti-HAV values > 10-20 IU/L are generally considered to be protective against infection. Assays to detect anti-HAV antibodies are used to determine an existing or past hepatitis A infection. They are also used to observe the immune response after HAV vaccination.
The hepatitis A virus is an RNA-containing virus that lacks an envelope. It belongs to the family of picornaviruses. To date, just one human serotype and 7 genotypes have been described. The viral capsid consists of 3 proteins (VP1-VP3) that form an immunodominant structure on the surface of the viral particle that is highly conserved between all genotypes. After vaccination or natural infection, the immune response is directed against this structure.
Hepatitis A is the most common form of acute viral hepatitis. It is transmitted by the fecal-oral route. The disease has not been known to take a chronic course, nor does the virus persist in the organism. The hepatitis A virus is one of the most common causes (10-20 %) of a fulminating course of viral hepatitis.
Total anti-HAV is positive at the onset of a hepatitis A infection (IgM). After natural infection, anti-HAV IgG antibodies can usually be detected lifelong and provide protection against the disease if the organism is reinfected. Vaccines against hepatitis A and combined vaccines against hepatitis A and B are available today. Upon vaccination against hepatitis A, anti-HAV IgG antibodies can be detected after 2 weeks. In the case of complete immunization, protection usually lasts for years. There is no limit value to define immune protection but anti-HAV values > 10-20 IU/L are generally considered to be protective against infection. Assays to detect anti-HAV antibodies are used to determine an existing or past hepatitis A infection. They are also used to observe the immune response after HAV vaccination.
Performing Laboratory
Frederick Health Laboratory
400 W 7th St
Frederick, MD 21701
Last Updated: December 28, 2023
